Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer.
Francesco Saverio MenniniAndrea MarcellusiGianluca FabianoLorenza RimassaArmando SantoroNicola PersoneniPublished in: Future oncology (London, England) (2019)
Aim: Cetuximab is used for the treatment of RAS wild-type metastatic colorectal cancer patients. Standard administration schedule is once a week; however, the bioequivalence of an every-other-week (EOW) schedule was demonstrated. Methods: We compared a base case scenario of 100% weekly administration to an EOW at 50 or 100%. Medical examinations, patient management and loss of productivity were considered. Results: Base case was estimated at €100.6 million versus €92.8 million and €84.9 million of EOW 50 and 100%, which showed a cost reduction of 8 and 16%, respectively. Indirect costs accounted for 65% in both scenarios. Conclusion: The adoption of an EOW administration schedule of cetuximab reduced direct and indirect costs substantially.
Keyphrases
- wild type
- metastatic colorectal cancer
- end stage renal disease
- climate change
- ejection fraction
- chronic kidney disease
- squamous cell carcinoma
- newly diagnosed
- small cell lung cancer
- healthcare
- prognostic factors
- peritoneal dialysis
- case report
- electronic health record
- randomized controlled trial
- patient reported outcomes
- rectal cancer
- smoking cessation
- study protocol